Gilead Sciences (GILD) Financials

Gilead Sciences Inc (GILD) is a leading biopharmaceutical company that focuses on the research, development, and commercialization of innovative medicines. The company's financials reflect its strong performance in the industry. GILD's income statement shows its revenue, expenses, and net income. The company reported total revenue of $22.45 billion in the most recent fiscal year. Its gross profit was $14.78 billion, indicating a healthy margin. Net income from stockholders was $5.39 billion, demonstrating GILD's ability to generate profits for its investors.

In terms of profitability, GILD's EBIT (earnings before interest and taxes) and EBITDA (earnings before interest, taxes, depreciation, and amortization) provide valuable insights. GILD's EBIT was $7.82 billion, while its EBITDA reached $10.91 billion. These figures illustrate the company's strong operational performance and efficiency in managing its resources. GILD's balance sheet reveals its financial position, including its assets, liabilities, and stockholders' equity. The company had total assets worth $68.07 billion and total liabilities of $29.92 billion. Stockholders' equity amounted to $38.15 billion, indicating a financially healthy position with a strong asset base.

GILD's cash flow statement is crucial in understanding its liquidity and ability to fund its operations. The company's cash equivalents play a significant role in ensuring its short-term liquidity. GILD reported cash equivalents of $2.56 billion, providing a cushion for its financial needs. Net debt is another important financial metric that reflects a company's leverage. GILD's net debt stood at $21.24 billion, indicating its debt obligations after accounting for its cash and cash equivalents.

The statement of cash flows further breaks down GILD's cash flow into operating, investing, and financing activities. Operating cash flow represents the cash generated from its core business operations. GILD's operating cash flow was $8.75 billion, indicating its ability to generate cash from its day-to-day operations. Investing cash flow represents the cash flow from the company's investments in assets and acquisitions. GILD's investing cash flow was $3.98 billion, reflecting its strategic investments in research and development, acquisitions, and other capital expenditures. Financing cash flow accounts for the cash flow from GILD's financing activities, including debt repayments, dividend payments, and share repurchases. GILD's financing cash flow was $1.36 billion, reflecting its capital structure management and returning value to its shareholders.

Lastly, free cash flow is a key metric that indicates a company's ability to generate cash after accounting for capital expenditures. GILD's free cash flow was $4.77 billion, demonstrating its ability to generate excess cash for future investments or returns to shareholders. Overall, Gilead Sciences Inc (GILD) has reported strong financials, with significant revenue, profitability, and cash flow generation. The company's sound financial position and ability to generate profits make it a reputable player in the biopharmaceutical industry.